Pfiz­er and Lil­ly's tanezum­ab large­ly makes the ef­fi­ca­cy cut in sec­ond PhI­II study, but safe­ty is­sues con­tin­ue to blight an­ti-NGF drug

Stark safe­ty is­sues in the field of an­ti-NGF pain drugs have led a num­ber of high pro­file drug­mak­ers to press pause on de­vel­op­ment, re­duce dos­es or aban­don their ef­forts al­to­geth­er. On Tues­day, Lil­ly and Pfiz­er’s of­fer­ing — tanezum­ab — large­ly passed muster in terms of ef­fi­ca­cy in pa­tients with os­teoarthri­tis (OA) pain in a late-stage study, but was un­able to shake off that safe­ty is­sue — trig­ger­ing ag­gres­sive os­teoarthri­tis in a small per­cent­age of pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.